Prostate Cancer Screening: What the New PSA Advice Means

You're 52, your annual physical is next month, and nobody has ever brought up a PSA test. Until this week, that silence was official policy. For 16 years the American Cancer Society told most men to "talk it over" with a doctor, and plenty of those talks never happened.

That changed on November 12. The society's new prostate cancer screening guideline now says plainly that men at average risk should get a PSA blood test every two years from age 50 to 69. Black men and men with a strong family history should start at 45 and test every year. Below is what changed, the trial that drove it, what the test can and can't tell you, and what it might cost you.

What the New Prostate Cancer Screening Guideline Says

The update, published in the society's journal CA: A Cancer Journal for Clinicians, swaps a conversation for a schedule. According to the American Cancer Society's announcement, the old 2010 guidance made no direct call for regular testing at all.

The new version sorts men by risk and age:

• Average risk, ages 50 to 69: a PSA test every two years.
• Black men, ages 45 to 69: a PSA test every year.
• Strong family history, ages 45 to 69: every year. "Strong" means a first-degree relative (father, brother or son) diagnosed before 65, or more than one first-degree relative diagnosed at any age.
• One first-degree relative diagnosed at 65 or older: every two years, starting at 45.
• Ages 70 to 74: a personal decision based on your health, life expectancy and preferences.
• Ages 75 to 79: not recommended, though very healthy men with a rising PSA may discuss continuing.
• 80 and older, or under 10 years of expected life: stop.

The society estimates 333,830 new diagnoses and 36,320 deaths from prostate cancer in the US this year. It is the second leading cause of cancer death in American men.

Why the Advice Flipped After 16 Years

The PSA test fell out of favor for a simple reason. It found too many cancers that would never have hurt anyone, and treating them caused real damage. Surgery and radiation can leave men with incontinence, erectile dysfunction and bowel problems.

What moved the society was time. The European Randomized Study of Screening for Prostate Cancer followed about 162,000 men, aged 55 to 69 when they joined, across eight countries. Its 23-year results, published in the New England Journal of Medicine, showed a 13% lower rate of prostate cancer death in the screened group.

The benefit grew as the years passed. At 16 years, 628 men had to be invited to screening to prevent one death. At 23 years, that number fell to 456. Prostate cancer is slow, so the payoff from finding it early also arrives slowly.

The second shift is in what happens after a high result. A decade ago, an abnormal PSA often led straight to a needle biopsy. Today, an MRI or a blood or urine biomarker test can screen out many men who don't need one. That cuts the harm side of the equation without touching the benefit side.

Your Odds, Worked Out in Real Numbers

Relative risk cuts sound bigger than they are. So picture 1,000 men like you, all invited to regular PSA screening for two decades, using the European trial's figures.

• About 2 of them avoid dying of prostate cancer. One death prevented per 456 men invited works out to roughly 2.2 per 1,000.
• For every death prevented, 12 men are diagnosed. Some of those 12 had cancers that would never have caused symptoms.
• So 2.2 deaths prevented means about 26 men diagnosed. That is simple multiplication of the trial's two published ratios (2.2 times 12), not a separate count from the study.
• The absolute drop in risk is 0.22 percentage points. The trial reported that figure alongside the 13% relative cut, as The ASCO Post summarized. Its summary also notes that cumulative prostate cancer diagnoses ran about 14% in the screened group against 12% in the unscreened group.

Here's the uncomfortable part. Most of the men in that group get no benefit at all, and a few get a diagnosis that changes their life for nothing. The guideline's bet is that MRI and active surveillance can shrink that second group far enough to make two lives per 1,000 clearly worth it.

Your own odds are not the average. Black men are 67% more likely to be diagnosed than White men and have nearly twice the death rate, according to the society. That is why the guideline moves their start age to 45 and their interval to every year.

What Happens If Your PSA Comes Back High

This is where the new guideline earns its keep. It lays out a step-by-step path designed to keep you away from an unnecessary biopsy.

1. Know the number. For men aged 45 to 69, the guideline treats a PSA of 3.0 ng/mL or higher as elevated. For 70 to 74, the line is 6.5. Many US lab reports still flag only values above 4.0 as abnormal, so read the actual number, not the "normal" label.
2. Repeat the test. PSA can jump after an infection, recent ejaculation or a long bike ride. The guideline says to retest between two weeks and three months later.
3. Get an MRI or a biomarker test. If the second result is still high, most men should be offered a prostate MRI, a validated biomarker test, or both, before any biopsy.
4. Biopsy only if those point to it. A biopsy is still the only way to diagnose cancer, but it carries risks of bleeding and infection.
5. Start with watching, not treating, if the cancer is low risk. Active surveillance means regular checks and treatment only if the cancer shows signs of growing.

One more signal matters. A PSA that keeps climbing over several tests worries doctors more than a single high reading. Keep copies of your results so you and your doctor can see the trend.

What Prostate Cancer Screening Costs You

The blood test itself is cheap. The follow-up is where bills can appear, and coverage has not caught up with the new advice.

If you have Medicare

Medicare Part B covers one PSA test every 12 months for men over 50, and you pay nothing for the test if your doctor accepts assignment. Any office visit or rectal exam is billed separately at 20% after the Part B deductible. If you're comparing plans right now, our breakdown of what Medicare open enrollment changes this year covers how those costs land in your total bill.

If you have private insurance

This is the gap. The US Preventive Services Task Force still rates PSA screening for men 55 to 69 as an individual decision (a "C" grade). Insurers must cover task force "A" and "B" services with no cost sharing, so a PSA test is not guaranteed to be free. The task force has said an update is coming.

Follow-up testing costs more. A University of Michigan study of privately insured men, published in the journal Cancer, found the median out-of-pocket bill for an MRI alone rose from $81 to $490 over a decade, and MRI plus biopsy reached $620. More than 75% of men who needed follow-up paid something.

A simple budget: if you're 50 and average risk, plan on a low-cost blood test every other year. Set aside roughly $500 to $650 in case you need an MRI or biopsy. Those costs are eligible expenses, so they fit neatly into the money you put in a flexible spending account. Our guide to how much to set aside in your FSA walks through that math.

Who Should Push for a PSA Test Now

Guidelines take years to reach every exam room, and other groups still disagree. The American Urological Association screens from 55 to 69 for average-risk men. The American Academy of Family Physicians does not recommend routine PSA screening at all. Your doctor may follow any of them.

So be ready to ask. You have the strongest case if you are:

• A Black man aged 45 or older who has never had a PSA test.
• A man of any background whose father or brother had prostate cancer, especially before 65.
• Between 50 and 69 with no PSA result in the last two years.
• Someone whose last PSA was between 3.0 and 4.0 and was marked "normal."

Prostate cancer, like type 2 diabetes that goes undetected for years, usually causes no symptoms early on. Five-year survival is above 99% when it is caught inside the gland, and falls to 38% once it spreads. Waiting for symptoms means waiting for the stage that's hardest to treat.

Frequently Asked Questions

At what age should men start getting a PSA test?

Under the American Cancer Society's new guideline, men at average risk should start at 50 and test every two years until 69. Black men and men with a strong family history should start at 45 and test every year.

What PSA level is considered high?

The guideline treats 3.0 ng/mL or higher as elevated for men aged 45 to 69, and 6.5 or higher for men aged 70 to 74. A high result should be repeated before any further testing.

Do you need a biopsy if your PSA is high?

Not right away. The guideline recommends repeating the PSA test, then offering an MRI or a biomarker test. A biopsy follows only if those results suggest cancer is likely.

Does insurance cover prostate cancer screening?

Medicare covers one PSA test a year for men over 50 at no cost for the test. Private plans vary, because the federal task force gives PSA screening a "C" grade, which does not require free coverage.

Is PSA screening worth it after 70?

For men aged 70 to 74, the guideline calls it a personal decision based on health and life expectancy. From 75 it is generally not recommended, and from 80 it should stop.

The Bottom Line on PSA Testing

The biggest cancer organization in the US now says most men in their 50s and 60s should get a PSA test every two years, and higher-risk men every year from 45. The evidence took 23 years to mature, and it shows a real but modest drop in deaths.

Your next step is small. At your next checkup, ask for your PSA number, not just a "normal" stamp, and ask what happens if it comes back high. A man who knows his number and the MRI-first path gets most of the benefit with far less of the risk.